Table 1.
Patient demographics and baseline characteristics
| Variable | Aml/Val (N = 2566) |
|---|---|
| Age, years | 52.6 ± 10.31 |
| Age ≥65 years, n (%) | 287 (11.2) |
| Sex, male, n (%) | 1563 (60.9) |
| Race, Caucasian, n (%) | 2370 (92.4) |
| BMI ≥30 kg/m2, n (%) | 1189 (46.3) |
| Diabetes mellitus, n (%) | 882 (34.4) |
| Essential hypertension, n (%) | 2504 (97.6) |
| Duration of hypertension, years | 7.9 ± 7.26 |
| Previous antihypertensive treatment, n (%) | 2025 (78.9) |
| Selective beta-blockers | 629 (24.5) |
| ACEIs | 533 (20.8) |
| Dihydropyridine derivatives | 405 (15.8) |
| Angiotensin II antagonists | 272 (10.6) |
| ACEIs and diuretics | 198 (7.7) |
| Angiotensin II antagonists and diuretics | 161 (6.3) |
| Selective beta-blocking agents and thiazides | 94 (3.7) |
| Thiazides (plain) | 58 (2.3) |
| Number of different antihypertensive drugs as prior treatment, n (%) | |
| 1 | 1322 (51.5) |
| 2 | 570 (22.2) |
| 3 | 112 (4.4) |
| >3 | 16 (0.6) |
| msSBP, mmHg | 164.4 ± 14.92 |
| msDBP, mmHg | 100.5 ± 8.63 |
| Concomitant antihypertensive treatment, n (%) | 662 (25.8) |
| Selective beta-blocking agents | 421 (16.4) |
| Selective beta-blocking agents and thiazides | 69 (2.7) |
Data are presented as mean ± SD, unless otherwise stated
ACEIs angiotensin II converting enzyme inhibitors, Aml/Val amlodipine/valsartan, BMI body mass index, msDBP mean sitting diastolic blood pressure, msSBP mean sitting systolic blood pressure, SD standard deviation